Bay Area Biotech Forum

From research to regulation, the biotech industry is taking a hit, but drug-development companies continue to press forward, moving important discoveries from the lab bench to the patient bedside.

The program will begin with a talk with Ultragenyx CEO Emil Kakkis, the scientist behind the first treatment for an ultra-rare genetic disease, and Ryan Dant, the first patient. Moderated by Ron Leuty.

Our panel will explore the macro issues and micro decisions shaping the Bay Area biotech ecosystem, along with the opportunities ahead.